CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing research activities on liver organoids
4.1.2. Increasing prevalence of non-alcoholic fatty liver disease
4.1.3. Rising initiatives to increase awareness about liver organoids
4.1.4. Increasing focus on developing alternatives for animal testing models
4.1.5. A significant increase in research funding and venture capital investments
4.2. Market Restraints & Challenges
4.2.1. Lack of skilled professionals
4.2.2. Issues related to the incorporation of organoids into existing workflows
4.3. Market Opportunities
4.3.1. Increasing demand for liver transplantation and healthcare market in developing
regions
4.3.2. Growing focus on drug discovery activities
CHAPTER 5. GLOBAL HUMAN LIVER MODELS MARKET – BY PLATFORM
5.1. Liver Organoids
5.2. Liver-On-A-Chip
5.3. 2D Models
5.4. Animal Models
5.5. 3D Bioprinting
CHAPTER 6. GLOBAL HUMAN LIVER MODELS MARKET - BY GEOGRAPHY
6.1. Introduction
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.2.3. Mexico
6.2.4. Costa Rica
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.3.3. Chile
6.3.4. Columbia
6.3.5. Others
6.4. Europe
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Netherlands
6.4.8. Switzerland
6.4.9. Poland
6.4.10. Others
6.5. APAC
6.5.1. China
6.5.2. Japan
6.5.3. India
6.5.4. South Korea
6.5.5. Australia & New Zealand
6.5.6. Malaysia
6.5.7. Singapore
6.5.8. Others
6.6. Middle East & Africa
6.6.1. UAE
6.6.2. Saudi Arabia
6.6.3. Iran
6.6.4. Iraq
6.6.5. Qatar
6.6.6. South Africa
6.6.7. Algeria
6.6.8. Morocco
6.6.9. Nigeria
6.6.10. Egypt
6.6.11. Others
CHAPTER 7. GLOBAL HUMAN LIVER MODELS MARKET - COMPANY
PROFILES
7.1. Mimetas B.V
7.2. InSphero AG
7.3. Organovo Holdings Inc.
7.4. Ascendance Biotechnology
7.5. Emulate, Inc.
7.6. CN Bio Innovations
7.7. Cyfuse Biomedical
7.8. ExVive Human Tissue Models
7.9. Promethera Biosciences LLC
7.10. Pandorum Technologies
7.11. Regeneron Pharmaceuticals, Inc.
7.12. Biogen, Inc.
7.13. Gilead Sciences
CHAPTER 8. GLOBAL HUMAN LIVER MODELS MARKET - COMPETITIVE
LANDSCAPE
8.1. Market Share Analysis
8.2. Strategies adopted by top companies
8.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 9. MARKET INSIGHTS
9.1. Industry Experts Insights
9.2. Analysts Opinions
9.3. Investment Opportunities
CHAPTER 10. APPENDIX
10.1. List of Tables
10.2. List of Figures
